Sponsor: GlaxoSmithKline
Sponsor Study ID: 221530 JADE
Study Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate Dostarlimab as Sequential Therapy After Chemoradiation in Patients With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
CTO #: 103960
NCT Number: NCT06256588
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Lip, Oral Cavity and Pharynx
Study Objectives: To evaluate the efficacy of dostarlimab as sequential therapy following CRT as compared to placebo in participants with PD-L1 positive LA unresected HNSCC as per BICR. To estimate the difference in overall survival (OS) for participants treated with dostarlimab as sequential therapy following CRT as compared to placebo in participants with LA unresected HNSCC.